Product
Sublingual allergy immunotherapy
1 clinical trial
3 indications
Indication
House Dust Mite AllergyIndication
Dermatophagoides PteronyssinusIndication
Allergic RhinitisClinical trial
A One-year Placebo-controlled Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) SLIT-tablet in Children (5-11 Years of Age) With HDM Allergic Rhinitis/Rhinoconjunctivitis With or Without AsthmaStatus: Active (not recruiting), Estimated PCD: 2023-04-01